Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious
Autoimmune Cytopenia (AIC) is a complication that occurs in 2-6% of the post-transplant paediatric population. It is a significant cause of morbidity and a therapeutic challenge. The first line treatment is often corticosteroids, and Rituximab is used in the second line. Refractoriness to several li...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Annals of Oncology Research and Therapy |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/aort.aort_30_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|